[go: up one dir, main page]

AR116951A1 - Sales cristalinas de un inhibidor de calicreína plasmática - Google Patents

Sales cristalinas de un inhibidor de calicreína plasmática

Info

Publication number
AR116951A1
AR116951A1 ARP190103187A ARP190103187A AR116951A1 AR 116951 A1 AR116951 A1 AR 116951A1 AR P190103187 A ARP190103187 A AR P190103187A AR P190103187 A ARP190103187 A AR P190103187A AR 116951 A1 AR116951 A1 AR 116951A1
Authority
AR
Argentina
Prior art keywords
crystalline salts
salt
inhibitor
plasma calicrein
plasma
Prior art date
Application number
ARP190103187A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Yahya El-Kattan
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70457981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR116951(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of AR116951A1 publication Critical patent/AR116951A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una sal cristalina caracterizada porque es del Compuesto I, de fórmula (1). Reivindicación 2: La sal cristalina de la reivindicación 1, caracterizada porque la sal es una sal clorhidrato. Reivindicación 3: La sal cristalina de la reivindicación 2, caracterizada porque la sal es una sal bis(clorhidrato).
ARP190103187A 2018-11-02 2019-10-31 Sales cristalinas de un inhibidor de calicreína plasmática AR116951A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02

Publications (1)

Publication Number Publication Date
AR116951A1 true AR116951A1 (es) 2021-06-30

Family

ID=70457981

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103187A AR116951A1 (es) 2018-11-02 2019-10-31 Sales cristalinas de un inhibidor de calicreína plasmática

Country Status (21)

Country Link
US (11) US10662160B1 (es)
EP (1) EP3873463A4 (es)
JP (2) JP2022505670A (es)
KR (1) KR102810837B1 (es)
CN (1) CN112969458A (es)
AR (1) AR116951A1 (es)
AU (1) AU2019374115B8 (es)
BR (1) BR112021008249A2 (es)
CA (1) CA3117123A1 (es)
CL (1) CL2021001094A1 (es)
CO (1) CO2021007172A2 (es)
EA (1) EA202191192A1 (es)
IL (2) IL322896A (es)
MA (1) MA54087A (es)
MX (1) MX2021004917A (es)
PE (1) PE20211280A1 (es)
PH (1) PH12021550883A1 (es)
SG (1) SG11202103804TA (es)
TW (1) TW202031255A (es)
UY (1) UY38438A (es)
WO (1) WO2020092898A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199131A (en) 2014-03-07 2023-10-17 Biocryst Pharm Inc Human plasma kallikrein inhibitors
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (en) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
MX2007006919A (es) 2004-12-15 2007-06-26 Bristol Myers Squibb Co Formas cristalinas de un inhibidor del factor xa.
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2571869B1 (en) 2010-05-19 2015-09-23 Sandoz AG Purification of posaconazole and posaconazole intermediates
EP2643314B1 (en) 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
MY199131A (en) * 2014-03-07 2023-10-17 Biocryst Pharm Inc Human plasma kallikrein inhibitors
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
MX2022001608A (es) 2019-08-06 2022-03-11 Biocryst Pharm Inc Sintesis de un inhibidor de calicreina plasmatica a escala de proceso.

Also Published As

Publication number Publication date
US20240109844A1 (en) 2024-04-04
US20250388545A1 (en) 2025-12-25
CN112969458A (zh) 2021-06-15
BR112021008249A2 (pt) 2021-08-03
AU2019374115B8 (en) 2025-08-07
AU2019374115B1 (en) 2025-07-17
IL322896A (en) 2025-10-01
SG11202103804TA (en) 2021-05-28
MA54087A (fr) 2022-02-09
US20250388548A1 (en) 2025-12-25
WO2020092898A1 (en) 2020-05-07
US20200140389A1 (en) 2020-05-07
JP2022505670A (ja) 2022-01-14
EP3873463A1 (en) 2021-09-08
US20250376448A1 (en) 2025-12-11
CA3117123A1 (en) 2020-05-07
AU2019374115A1 (en) 2021-06-03
US11618733B2 (en) 2023-04-04
PE20211280A1 (es) 2021-07-19
EP3873463A4 (en) 2022-06-22
US20250388546A1 (en) 2025-12-25
KR102810837B1 (ko) 2025-05-20
TW202031255A (zh) 2020-09-01
US10662160B1 (en) 2020-05-26
US20220204454A1 (en) 2022-06-30
US12344585B2 (en) 2025-07-01
CO2021007172A2 (es) 2021-06-10
PH12021550883A1 (en) 2022-02-21
US11117867B2 (en) 2021-09-14
US20250388547A1 (en) 2025-12-25
US20250388549A1 (en) 2025-12-25
UY38438A (es) 2020-05-29
EA202191192A1 (ru) 2021-09-23
MX2021004917A (es) 2021-06-18
JP2024109860A (ja) 2024-08-14
CL2021001094A1 (es) 2021-10-15
US20200308118A1 (en) 2020-10-01
IL282454A (en) 2021-06-30
KR20210087037A (ko) 2021-07-09
US20250376447A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
CO2020014586A2 (es) Compuestos
AR119672A1 (es) Inhibidor de 15-pgdh
EA202193015A1 (ru) Ингибиторы cdk
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
AR111960A1 (es) Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
CL2017000705A1 (es) Nuevos compuestos
AR105967A1 (es) Sales de un inhibidor de pim quinasa
NZ764644A (en) Oxy-fluoropiperidine derivative as kinase inhibitor
UY39832A (es) Inhibidores de cdk2
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
ECSP17054980A (es) Inhibidores selectivos de bace1
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CL2018001067A1 (es) Compuesto piranodipiridínico.
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
CO2020001471A2 (es) Compuesto pentacíclico
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
MY193239A (en) Novel b-lactamase inhibitors
CL2022001511A1 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina